Drugs in MeSH Category Teratogens

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms Ny	ISOTRETINOIN	isotretinoin	CAPSULE;ORAL	216097-003	Oct 7, 2025	AB2	RX	No	No
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-005	Nov 5, 2019		DISCN	Yes	No	9,750,711		Y
Upsher Smith Labs	ISOTRETINOIN	isotretinoin	CAPSULE;ORAL	212333-002	Sep 21, 2021	AB2	RX	No	No
Amneal Pharms Ny	ISOTRETINOIN	isotretinoin	CAPSULE;ORAL	216097-005	Oct 7, 2025	AB2	RX	No	No
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-003	Nov 5, 2019		DISCN	Yes	No	9,700,535		Y
Actavis Labs Fl	ISOTRETINOIN	isotretinoin	CAPSULE;ORAL	205063-006	Mar 31, 2021	AB2	RX	No	No

Market Dynamics and Patent Landscape for Drugs in the NLM MeSH Class: Teratogens

Last updated: December 17, 2025

Summary

The classification of teratogenic drugs under the Medical Subject Headings (MeSH) by the National Library of Medicine (NLM) encompasses agents known to cause developmental anomalies during embryogenesis. The market for teratogens is uniquely complex, driven by factors including regulatory scrutiny, ethical considerations, patent expirations, and changing prescribing patterns. This report explores the current market landscape, patent trends, competitive dynamics, and regulatory influences shaping the teratogen drug segment.

What defines drugs in the NLM MeSH Class: Teratogens?

MeSH Classification:

• The MeSH term "Teratogens" categorizes agents associated with fetal abnormalities.
• Key drugs include thalidomide, valproate, carbamazepine, phenytoin, and misoprostol.
• These agents span categories such as anticonvulsants, antibiotics, and chemotherapeutics.

Clinical relevance:

• Use of many teratogenic drugs is contraindicated during pregnancy; however, some are used with caution due to their therapeutic benefits (e.g., valproate for epilepsy).
• The market is influenced by risk management programs, patient monitoring, and alternative therapies.

---

What are the key market drivers and constraints affecting teratogenic drugs?

Market Drivers	Constraints
Increasing prevalence of conditions treated by teratogenic drugs (e.g., epilepsy, cancer)	Stringent regulatory requirements on drug safety during pregnancy
Advances in pharmacovigilance and risk management tools	Ethical concerns limiting clinical trials involving pregnant women
Patent expirations providing generic competition	Liability risk and litigation related to fetal harm cases
Emerging replacement therapies with lower teratogenic risk	Limited pipeline due to safety considerations

Market Size & Growth

The global market for teratogenic drugs was valued at approximately $1.4 billion in 2021, projected to grow at a CAGR of 3-4% through 2028. Growth is driven particularly by the expansion of anticonvulsant and oncology segments.

Key Regional trends:

Region	Market Size (2021)	CAGR (2022-2028)	Main Drivers
North America	$550 million	3.2%	Regulatory tightening, high epilepsy prevalence
Europe	$350 million	3.5%	Patent expirations, increased awareness
Asia-Pacific	$300 million	4.1%	Growing healthcare infrastructure
Rest of World	$200 million	3.8%	Increasing access, emerging markets

Major Therapeutic Segments

Segment	Key Drugs	Approximate Market Share	Examples of Monitored Drugs
Anticonvulsants	Valproate, Carbamazepine, Phenytoin	55%	Valproate (~$540M, 2021)
Oncology	Thalidomide, Lenalidomide	25%	Thalidomide (~$250M)
Other	Antibiotics (e.g., chloramphenicol), Hormones	20%	Misoprostol (~$80M)

---

What is the patent landscape surrounding teratogenic drugs?

Patent Trends & Lifecycle

Phase	Typical Duration	Characteristics	Examples
Innovator	10-20 years	Market exclusivity; high R&D costs	Thalidomide patents (expired)
Patent Expiry	2020-2035+	Generic entry; price erosion	Valproate patents (expired in multiple countries)
Post-Patent / Biosimilars	N/A	Market competition intensifies	Lenalidomide biosimilars in development

Patent Status of Major Drugs (as of 2023)

Drug	Original Patent Expiry	Current Patent Status	Generic Presence	Notable Patents & Litigation
Valproate (Valproic acid)	2008 (various jurisdictions)	Patent expired	Widely generic	N/A
Thalidomide	1960s	Patents long expired	Several generics	Patent challenges in India
Lenalidomide	2024 (expected)	Active patent life	Limited generics	Patent disputes ongoing
Misoprostol	Market exclusivity ended in 1980s	Generics available	High competition	N/A

Patent Strategies & Challenges

• Innovators seek secondary patents on formulations, delivery devices, or indications.
• Generics challenge patents via Paragraph IV filings, with legal battles influencing market entry.
• Biosimilars and me-too compounds are emerging, especially in oncology.

---

How do regulatory policies influence the market and patent strategies?

Regulatory Frameworks

Regulatory Agency	Key Policies	Impact on Teratogens
FDA (USA)	REMS programs, pregnancy registries	Tight surveillance, conditioning approvals
EMA (Europe)	Pregnancy prevention programs	Restrictive use, monitoring
PMDA (Japan)	Post-marketing surveillance	Increased compliance costs
WHO	Drug safety communications	Global awareness campaigns

Specific Regulatory Impacts

• Risk Minimization: REMS (Risk Evaluation and Mitigation Strategies) for drugs like valproate, including patient counseling and pregnancies registries.
• Post-Approval Monitoring: Enhance pharmacovigilance, delaying or restricting approvals.
• Labeling & Warnings: Expanded warnings on teratogenicity lead to reduced prescribing, affecting revenue.

---

What are the competitive dynamics among teratogenic drugs?

Market Players

Company	Key Drugs	Patent Status	Strategy	Notes
Johnson & Johnson	Thalidomide derivatives	Patents expired	Diversified portfolio	Focus on oncology
Teva Pharmaceuticals	Valproate generics	Patent expired	Price competition	Extensive regional footprint
Celgene (BMS)	Lenalidomide	Active patent	Patent defense & pipeline	Key in multiple myeloma
Others	Various	N/A	Licensing, biosimilars	Focus on patient safety

Market Entry Barriers

• High safety profile requirements
• Patent protections and legal hurdles
• Ethical constraints on clinical trials involving pregnant women

---

What are the emerging trends and future opportunities?

Innovations & Future Directions

Trend	Description	Implication
Safer Alternatives	Development of non-teratogenic drugs	Market expansion, reduced litigation
Biologics & Biosimilars	Targeted therapies with lower teratogenic risk	Competitive advantage
Digital Pharma & Monitoring	Digital pregnancy registries, pharmacovigilance	Improved safety monitoring
Regulatory Reforms	Updated guidelines for drug approval during pregnancy	Accelerated access to safer drugs

Market Opportunities

• Replacing existing teratogens with safer, patent-protected agents
• Expanding access in emerging regions with increasing healthcare investments
• Leveraging digital tools for enhanced risk management

---

Conclusion

The teratogen class under the NLM MeSH reflects a complex intersection of therapeutic necessity, safety regulation, and patent dynamics. While the overall market remains relatively stable, innovation driven by safety concerns and regulatory pressures presents both challenges and opportunities. Key strategic focuses include patent management, diversification of therapeutic pipelines, and advancements in safer drug profiles.

---

Key Takeaways

• The global market for teratogenic drugs was valued at ~$1.4 billion in 2021, with modest growth driven by anticonvulsant and oncology segments.
• Patent expirations are paving the way for generic entry, intensifying price competition and revenue decline for original innovators.
• Regulatory frameworks such as REMS significantly influence drug usage, market access, and manufacturer strategies.
• Litigation, patent challenges, and biosimilar developments will shape future market dynamics.
• The pursuit of safer therapeutic alternatives and digital pharmacovigilance are emerging as pivotal growth areas.

---

FAQs

Q1: What are the primary challenges facing patent owners of teratogenic drugs?
A1: Patent expiration leads to generic competition, eroding market exclusivity. Patent litigations and challenges often follow expiry, and regulatory restrictions on safety and labeling further limit market potential.

Q2: How do regulatory agencies influence the pricing of teratogenic drugs?
A2: Strict safety requirements and risk mitigation programs can restrict drug use, impact dosing guidelines, and drive up costs associated with compliance and post-marketing surveillance, indirectly affecting pricing.

Q3: Are there ongoing efforts to develop non-teratogenic alternatives?
A3: Yes. Increased focus on safer drugs in oncology and neurology, alongside biologics and targeted therapies, aims to reduce teratogenic risks and expand treatment options.

Q4: Which geographic regions present the most growth opportunities?
A4: The Asia-Pacific region exhibits higher CAGR (~4.1%), fueled by expanding healthcare infrastructure and increasing regulatory approvals. Emerging markets are also opening up for biosimilars and generics.

Q5: What role does digital health play in the future of teratogen management?
A5: Digital platforms improve pharmacovigilance, enable pregnancy registries, and facilitate real-time monitoring, enhancing safety and compliance, which could influence market dynamics favorably.

---

References

[1] Grand View Research, “Teratogenic Drugs Market Size & Trends,” 2022.
[2] U.S. Food & Drug Administration, “Pregnancy and Lactation Labeling Rule (PLLR),” 2015.
[3] WHO, “Guidelines on Teratogenic Risks of Medications,” 2019.
[4] Euromonitor International, “Global Pharmaceuticals Market Overview,” 2022.
[5] MarketWatch, “Patent Expirations and Generic Entry Trends in Pharmaceuticals,” 2023.